The board ("Board") of directors ("Directors") of the Jenscare Scientific Co., Ltd. announce that, following the enrollment in the Total Product Life Cycle Advisory Program ("TAP") pilot of the U.S. Food and Drug Administration ("FDA"), Lux-Valve Plus has been selected for the Expert Panel Scientific Advice Pilot as at the date of issuance of this announcement. The Expert Panel Scientific Advice Pilot, launched by the European Medicines Agency ("EMA"), aims to give scientific advice on the intended clinical development strategy and proposals for the clinical investigation of certain high-risk medical devices, as well as promote innovation and faster patient access to safer and more effective devices. The EMA is a decentralized agency of the European Union ("EU") responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.

The expert panels will provide advice to the Company on the clinical development strategy and/or for the clinical investigation of Lux-Valve Plus. This is expected to accelerate the clinical development and registration progress of Lux-Valve Plus for CE marking in Europe, expand the global reach and facilitate the internationalization progress of the product.